Ovarian Cancers (eBook)

Eric Pujade-Lauraine, MD, PhD, is founder of the French GINECO Group, which is devoted to clinical research in gynecologic cancer. He is head of the Women Cancer and Clinical research Department  at Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, AP-HP  in Paris, France and co-chair of the French gynecologic rare tumor network (TMRG)While receiving his medical degree from the University of Paris VI, Professor Pujade-Lauraine later obtained his PhD degree from the University of Paris VI. He is now professor of Medical Oncology at University Paris Descartes. As well as serving on several advisory boards, Prof Pujade-Lauraine is member of the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the European Society of Gynaecologic Oncology (ESGO). He is  also Member of the Executive Board of the European Network of Gynecological Trials (ENGOT) and of the international Gynecologic Cancer Intergroup (GCIG) and is past-chair of this institution. He is co-founder and past Chair of the Gynecologic Cancer Academy (GCA) and of the ENGOT Translational  group. He was until 2014 member of the NCI Gynecologic Cancer Steering Committee. Prof Pujade-Lauraine has co-authored more than 160 peer-reviewed articlesIsabelle Ray-Coquard, MD, PhD, is medical oncologist in the Medical Oncology Department and the Institute for Clinical Science at the Centre Leon Berard, the regional Cancer Center in Lyon, France. Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the factors that determine medical practices in oncology. Prof Ray-Coquard also received Master’s degrees in medical economy in 1996 and in statistics in1995. Since 2005, Prof Ray-Coquard has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national observatory dedicated to rare ovarian cancer (www.ovaire-rare.org), a network funded by the INCA commission and dedicated to the management of all rare ovarian cancer. At the Groupe d’investigateurs national evaluation des cancers de l’ovaire (GINECO), Pr. Ray-Coquard has been active in the translational research advisory committee, the scientific committee, the rare tumors committee, and as a chairman of endometrial cancer subgroup. She is the current Past-President of GINECO. Since 2012, Prof Ray-Coquard is the chairman (with Jonathan Ledermann, UK as co chair) of the rare cancer working group from GCIG (gynaecological cancer intergroup) dedicated to clinical trials in the field of all gynaecological cancers. Prof Ray-Coquard is an active member of a number of professional groups, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation and the European Society of Medical Oncology. Prof Ray-Coquard has co-authored more than 160 peer-reviewed articles and over 200 abstracts and book chapters with an H factor of 36.Fabrice Lécuru, MD, PhD is a gynaecologic surgeon in the Surgical Oncology Department for Breast and Gynaecology in the Georges Pompidou European Hospital and Paris V – René Descartes University. He obtained a medical degree in Lille (1991), a PhD in Paris V University (1997) and a full Professorship in Paris V University (1998). He is head of department since 2007. His fields of interest and expertise are advanced laparoscopy for gynaecologic malignancies, robotic surgery and radical surgery for advanced ovarian cancers. Fabrice Lécuru is involved in teaching (Co-chairman of European Inter-University Diploma of Gynaecologic Oncology with Pr E Pujade Lauraine, Pr F Golfier and Pr F Kridelka).He developed experimental studies to assess the impact of pneumoperitoneum on tumor cell diffusion and migration. He is also involved in clinical research as PI (clinical trials on sentinel node biopsy in cervical cancer and preservation of lower limb lymphatic drainage) or associated investigator in more than 15 trials. He belongs to the Groupe d’investigateurs national d’evaluation des cancers de l’ovaire (GINECO) and is head of the « surgical sub-group » within the GINECO. Prof Fabrice Lécuru is an active member of scientific societies, including the American Society of Clinical Oncology, the Society of Gynecologic Oncology, the European Society of Gynaecologic Oncology, the International Gynecologic Cancer Society and of the EORTC organization. Prof Fabrice Lécuru has co-authored more than 110 peer-reviewed articles in international journals

PART 1: OVARIAN CANCER MANAGEMENTChapter 1. Clinical research in Europe dedicated to ovarian cancersE. Pujade-Lauraine, Paris, France Chapter 2. Genetics of ovarian carcinomasClaire Sénéchal, Bruno Buecher, Antoine de Pauw, Claude Houdayer, Etienne Rouleau, Catherine Noguès, Dominique Stoppa-LyonnetChapter 3. Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality Fabrice Lécuru, Charlotte Ngo, Anne Sophie Bats, Chérazade Bensaid, Pierre Combe, Eric Pujade Lauraine, Marie Aude le Frère Belda, Laure FournierChapter 4. How to evaluate tumor burden before therapeutic decisionA. Fagotti, L. Pedone Anchora, M. Pacciani, G. ScambiaChapter 5. Value of lymphadenectomyPhilipp Harter, Florian Heitz, Andreas du BoisChapter 6. HYPEC: what is the evidence?  Jean-Marc ClasseChapter 7. Onco-fertility applied to ovarian cancersEnrica Bentivegna, Sebastien Gouy, Catherine Uzan, Marcos Ballester, Catherine Poirot, Emile Daraï, Philippe MoriceChapter 8. First-line systemic therapy (chemo/antiangiogenics) Sandro Pignata, Sabrina Cecere Chapter 9.Elderly C. Falandry, Lyon, FranceChapter 10. Treatment at relapse (surgery  & Systemic  treatments)J. Pfisterer,  A. FloquetChapter 11. The future in ovarian cancers & place of the new immunotherapies in ovarian cancersHolbrook E.K. Kohrt , Amani Makkouk, Cariad ChesterPART 2: PARTICULAR TYPES OF OVARIAN CANCERS (for each:  histology and molecular specificities, specificity for surgery and management in first line and relapse)Chapter 12. High Grade Carcinomas, BRCA mutations and the role of PARP inhibitorsJonathan A LedermannChapter 13. Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or PeritoneumDavid M. GershensonChapter 14. Clear Cell carcinomaMasashi Takano, Satoshi Takakura, Keiichii FujiwaraChapter 15. Endometrioid carcinoma Laure de Cock, Gerlinde Averous, Philippe Barthélémy, Jean-Emmanuel KurtzChapter 16. Mucinous  carcinomaJubilee Brown, MD AndersonChapter 17. Uterine and Ovarian CarcinosarcomaD. Berton-Rigaud, JS Frenel, I Ray-CoquardChapter 18. Malignant Ovarian Germ Cell Tumours;  an overview of management and controversiesDr Costi Alifrangis, Professor Michael J SecklGarbi Annalisa, Achilarre Maria Teresa, Colombo NicolettaChapter 20. Very rare ovarian malignant tumors including small cell carcinoma Patricia Pautier